Article Text

Download PDFPDF
Short report
Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism
  1. Hanny Al-Samkari1,2,
  2. Gregory D Snyder3,
  3. Sarah Nikiforow2,
  4. Sara M Tolaney2,
  5. Rachel A Freedman2,
  6. Julie-Aurore Losman2,4
  1. 1 Center for Hematology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
  2. 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
  3. 3 Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
  4. 4 Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
  1. Correspondence to Dr Julie-Aurore Losman, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Julieaurore_Losman{at}dfci.harvard.edu

Footnotes

  • Contributors HAlS designed the case report, collected data, analysed data, and wrote and revised the manuscript. GDS collected data, analysed data and wrote the manuscript. SN provided expertise in haemophagocytic lymphohistiocytosis and critically revised the manuscript. SMT and RAF provided expertise in breast cancer and revised the manuscript. JAL designed the case report, oversaw writing of the manuscript and critically revised the manuscript.

  • Disclaimer No funding, writing support or other assistance was obtained from Eisai or Merck & Company by the authors. Neither Eisai nor Merck & Company had influence on the contents of the manuscript.

  • Competing interests HA: consultancy, Agios Pharmaceuticals. SN: advisory board member, Kite Pharmaceuticals. SMT: institutional funding from Genentech, Eli Lilly, Novartis, Pfizer, Exelixis, Bristol Myers Squibb, Eisai, AstraZeneca, Merck, Nektar; served on advisory boards for Genentech, Eli Lilly, Novartis, Pfizer, Exelixis, Merck, Bristol Meyers Squibb, Eisai, AstraZeneca, Nektar, Puma, Nanostring. RAF: institutional funding only from Eisai and Puma Biotechnology. JAL: institutional funding from Eli Lilly, Bayer. GDS has nothing to disclose.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors HAlS designed the case report, collected data, analysed data, and wrote and revised the manuscript. GDS collected data, analysed data and wrote the manuscript. SN provided expertise in haemophagocytic lymphohistiocytosis and critically revised the manuscript. SMT and RAF provided expertise in breast cancer and revised the manuscript. JAL designed the case report, oversaw writing of the manuscript and critically revised the manuscript.

  • Disclaimer No funding, writing support or other assistance was obtained from Eisai or Merck & Company by the authors. Neither Eisai nor Merck & Company had influence on the contents of the manuscript.

  • Competing interests HA: consultancy, Agios Pharmaceuticals. SN: advisory board member, Kite Pharmaceuticals. SMT: institutional funding from Genentech, Eli Lilly, Novartis, Pfizer, Exelixis, Bristol Myers Squibb, Eisai, AstraZeneca, Merck, Nektar; served on advisory boards for Genentech, Eli Lilly, Novartis, Pfizer, Exelixis, Merck, Bristol Meyers Squibb, Eisai, AstraZeneca, Nektar, Puma, Nanostring. RAF: institutional funding only from Eisai and Puma Biotechnology. JAL: institutional funding from Eli Lilly, Bayer. GDS has nothing to disclose.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.